Supreme Court Advocate Jonas W. Myhre, MCL, Hjort Law Office, DA
1. Summary
The article discusses the issue of marketing authorisation (MA) for parallel imported medicinal products (MP) in cases where the initially directly imported MP is withdrawn and a new variant of the same product is registered and granted MA.
It is suggested that with ECJ judgment 16 December 1999 in case C- 94/98, Rhone Poulenc Rorer Ltd ( Zimovane), a standard has been set which may be applicable in these instances. The identity requirement has been modified, as the MPs to be compared do not have to be "identical in all respects". The further test is tied to public health considerations. The two MPs must firstly fulfil the basic requirement of having the "same active ingredient and same therapeutic effect" and secondly that the MP in question does not "pose a problem of quality, efficacy or safety".